Want to see SRPT full AI Analyst Report?
SRPT Stock Chart & Stats
$21.55
$1.44(1.16%)
At close: 4:00 PM EST
$21.55
$1.44(1.16%)
Day’s Range― - ―
52-Week Range$10.42 - $25.32
Previous CloseN/A
Volume185.86K
Average Volume (3M)3.57M
Market Cap
$1.82B
Enterprise Value$3.04K
Total Cash (Recent Filing)$653.19M
Total Debt (Recent Filing)$1.04B
Price to Earnings (P/E)27.1
Beta1.29
Next Earnings
Aug 05, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.62
Shares Outstanding105,576,225
10 Day Avg. Volume3,208,661
30 Day Avg. Volume3,572,164
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.03
P/FCF Ratio-7.33
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.93Price Target Upside6.42% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)3.67
Revenue Forecast (FY)$1.83B
Bulls Say, Bears Say
Bulls Say
Improving ProfitabilitySarepta's return to GAAP and non‑GAAP operating profitability demonstrates the business can generate sustainable operating earnings from its core commercial portfolio. Durable operating profits support reinvestment in R&D and commercialization and reduce reliance on external financing over the next 2–6 months.
High Gross MarginsConsistently high unit gross margins indicate favorable product economics for Sarepta's therapies, especially exon‑skipping products and gene therapy. These margins provide structural cushion to fund SG&A and R&D, improving cash conversion potential and margin sustainability through execution cycles.
Strong Cash Position & Funding CapabilityA sizable cash balance and management's stated ability to fund multiple programs without equity raises materially reduces short‑term financing risk. This financial flexibility supports multi‑year clinical development and commercialization plans, lowering dilution risk and enabling strategic investment choices.
Bears Say
Revenue Volatility And Recent DeclineAlevitus revenue softness and overall YoY decline highlight dependence on a single, lumpy one‑time therapy for outsized quarter impacts. This structural revenue volatility complicates forecasting, increases earnings variability, and makes sustaining topline growth and investor confidence more challenging over coming quarters.
Inconsistent Cash GenerationWhile TTM cash flow improved, the divergence between net income and free cash flow and a recent drop in FCF point to unstable cash conversion. If sustained, weak cash conversion could constrain R&D investment pacing or require future financing when one‑time collaboration receipts are absent.
Clinical & Regulatory Uncertainty For Non‑Ambulatory UseKey regulatory outcomes hinge on small, open‑label cohorts and surrogate endpoints, leaving approval and label expansion uncertain. A negative or inconclusive result could restrict market expansion for non‑ambulatory patients, limiting long‑term revenue upside and complicating payer coverage decisions.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics Inc.’s price range in the past 12 months?
Sarepta Therapeutics Inc. lowest stock price was $10.41 and its highest was $25.32 in the past 12 months.
What is Sarepta Therapeutics Inc.’s market cap?
Sarepta Therapeutics Inc.’s market cap is $1.82B.
When is Sarepta Therapeutics Inc.’s upcoming earnings report date?
Sarepta Therapeutics Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 15 days.
How were Sarepta Therapeutics Inc.’s earnings last quarter?
Sarepta Therapeutics Inc. released its earnings results on May 06, 2026. The company reported $2.88 earnings per share for the quarter, beating the consensus estimate of $0.976 by $1.904.
Is Sarepta Therapeutics Inc. overvalued?
According to Wall Street analysts Sarepta Therapeutics Inc.’s price is currently Undervalued.
Does Sarepta Therapeutics Inc. pay dividends?
Sarepta Therapeutics Inc. does not currently pay dividends.
What is Sarepta Therapeutics Inc.’s EPS estimate?
Sarepta Therapeutics Inc.’s EPS estimate is 0.22.
How many shares outstanding does Sarepta Therapeutics Inc. have?
Sarepta Therapeutics Inc. has 105,576,225 shares outstanding.
What happened to Sarepta Therapeutics Inc.’s price movement after its last earnings report?
Sarepta Therapeutics Inc. reported an EPS of $2.88 in its last earnings report, beating expectations of $0.976. Following the earnings report the stock price went down -9.683%.
Which hedge fund is a major shareholder of Sarepta Therapeutics Inc.?
Currently, no hedge funds are holding shares in SRPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.93 (6.42% Upside)
$22.93 (6.42% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 4.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.27%
Trailing 12-Months
Company Description
Sarepta Therapeutics Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
SRPT Stock 12 Month Forecast
Average Price Target
$22.93
▲(6.42% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Ownership Overview
5.47% Insiders
16.97% Mutual Funds
0.53% Other Institutional Investors
42.46% Public Companies and
Individual Investors